CLNV Clean Vision Corp
Industrial Organic Chemicals · OTC · SEC CIK 1391426 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY40.2%
TTM net income YoY-21.0%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin92.2%
Operating margin-3,321.9%
Net margin-5,547.7%
FCF margin—
EBITDA margin-3,226.7%
Returns
ROE—
ROA-88.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets174.2%
Debt / equity—
Current ratio0.30x
Interest coverage-1.71x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-30.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $231,040 | $257,414 |
| Cost of revenue | $11,431 | $94,625 |
| Gross profit | $219,609 | $162,789 |
| R&D expense | $334,639 | $244,688 |
| SG&A expense | $1.18M | $1.07M |
| Operating income | -$7.31M | -$8.67M |
| Interest expense | $5.55M | $4.80M |
| Pretax income | -$14.18M | -$14.40M |
| Net income | -$14.00M | -$14.27M |
| EBITDA | -$7.09M | -$8.65M |
| EPS (basic) | -0.02 | -0.03 |
| EPS (diluted) | -0.02 | -0.03 |
| Weighted avg. shares (diluted) | 712.83M | 503.76M |
| Balance sheet | ||
| Cash & equivalents | $1.30M | $339,921 |
| Receivables | $37,624 | $70,745 |
| Current assets | $3.42M | $852,547 |
| PP&E, net | $4.79M | $4.88M |
| Goodwill | $4.85M | $4.85M |
| Total assets | $13.07M | $10.59M |
| Current liabilities | $18.45M | $11.28M |
| Long-term debt | $1.75M | $1.75M |
| Total debt | $1.75M | $1.75M |
| Total liabilities | $24.97M | $13.03M |
| Shareholders' equity | -$11.90M | -$4.24M |
| Net debt | $447,568 | $1.41M |
| Shares outstanding | 807.61M | 682.46M |
| Cash flow statement | ||
| Operating cash flow | -$4.87M | -$4.70M |
| Investing cash flow | -$132,877 | -$2.08M |
| Financing cash flow | $5.94M | $7.10M |
| Depreciation & amortization | $221,818 | $22,439 |
| Stock-based compensation | $714,000 | $945,600 |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.